Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Dec 22;66(50):1379-1382.
doi: 10.15585/mmwr.mm6650a3.

CDC Grand Rounds: National Amyotrophic Lateral Sclerosis (ALS) Registry Impact, Challenges, and Future Directions

Paul Mehta, D Kevin Horton, Edward J Kasarskis, Ed Tessaro, M Shira Eisenberg, Susan Laird, John Iskander

CDC Grand Rounds: National Amyotrophic Lateral Sclerosis (ALS) Registry Impact, Challenges, and Future Directions

Paul Mehta et al. MMWR Morb Mortal Wkly Rep. .

Erratum in

  • Erratum: Vol. 66, No. 50.
    [No authors listed] [No authors listed] MMWR Morb Mortal Wkly Rep. 2018 Jan 19;67(2):81. doi: 10.15585/mmwr.mm6702a8. MMWR Morb Mortal Wkly Rep. 2018. PMID: 29346341 Free PMC article. No abstract available.

Abstract

Amyotrophic lateral sclerosis (ALS), commonly known as Lou Gehrig's disease, is a rapidly progressive fatal neurologic disease. Currently, there is no cure for ALS and the available treatments only extend life by an average of a few months. The majority of ALS patients die within 2-5 years of diagnosis, though survival time varies depending on disease progression (1,2). For approximately 10% of patients, ALS is familial, meaning it and has a genetic component; the remaining 90% have sporadic ALS, where etiology is unknown, but might be linked to environmental factors such as chemical exposures (e.g., heavy metals, pesticides) and occupational history (3).

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: No conflicts of interest were reported.

Figures

FIGURE
FIGURE
Methodology* for identification of amyotrophic lateral sclerosis (ALS) cases for inclusion in the National ALS Registry — United States, 2013 * International Classification of Diseases, Ninth Revision (ICD-9) code, frequency of neurology visits, prescription drug use.
See this image and copyright information in PMC

References

    1. Miller RG, Jackson CE, Kasarskis EJ, et al.; Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2009;73:1218–26. 10.1212/WNL.0b013e3181bc0141 - DOI - PMC - PubMed
    1. Miller RG, Jackson CE, Kasarskis EJ, et al.; Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2009;73:1227–33. 10.1212/WNL.0b013e3181bc01a4 - DOI - PMC - PubMed
    1. Bettencourt C, Houlden H. Exome sequencing uncovers hidden pathways in familial and sporadic ALS. Nat Neurosci 2015;18:611–3. 10.1038/nn.4012 - DOI - PubMed
    1. US Public Health Service. ALS Registry Act. Washington, DC: 110th Congress. Public Law 2008;122 Stat 4047:110–373.
    1. Bryan L, Kaye W, Antao V, Mehta P, Muravov O, Horton DK. Preliminary results of national amyotrophic lateral sclerosis (ALS) registry risk factor survey data. PLoS One 2016;11:e0153683. 10.1371/journal.pone.0153683 - DOI - PMC - PubMed